ClinicalTrials.gg
TerminatedNCT05239182RiLEYUpdated Jul 17, 2025Results posted

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

A Phase 2 interventional study of 9-ING-41 and Retifanlimab in Pancreatic Adenocarcinoma, sponsored by Anwaar Saeed. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Anwaar Saeed · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Backbone chemo regimen of gemzar/abraxane no longer most favorable treatment for pancreatic cancer patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease progression.

Read the detailed description

Given the role of GSK-3β in immune regulation, the combination of GSK-3β inhibition with PD 1 inhibition may be expected to provide synergistic anti-tumor efficacy. The excellent safety profile of 9-ING-41, along with preclinical and clinical evidence of anti-tumor activity in pancreatic cancer, provides a strong rationale to evaluate the efficacy of 9-ING-41 in combination with a PD 1 inhibitor plus standard chemotherapy (gemcitabine/nab-paclitaxel) as frontline therapy for patients with advanced PDAC.

The combination of 9-ING-41 and retifanlimab with gemcitabine/nab-paclitaxel has not previously been administered to human subjects. In the 1801 study, 9-ING- 41 has been administered in combination with various chemotherapy regimens including gemcitabine/nab-paclitaxel, with one 9-ING-41-related SAE (transient visual change) documented to date. Retifanlimab alone has been well-tolerated when administered for up to 2 years in patients with anal cancer. Overall, based on previous nonclinical and clinical experience, both of these agents appear to have an acceptable safety profile and do not appear to have significant overlapping toxicities. However, it is possible that when they are administered together and in combination with gemcitabine/nab-paclitaxel, more frequent or severe AEs, or new AEs not previously observed with any of these agents administered alone, may occur.

It is not known if administration of 9-ING-41 and retifanlimab will act synergistically to provide increased anti-tumor activity compared to gemcitabine/nab-paclitaxel alone. Subjects in this study should not expect to benefit directly by their participation in the study. The data collected in this study may benefit future cancer patients.

02

Conditions studied

  • Pancreatic Adenocarcinoma

Keywords

  • glycogen biosynthesis
  • Glycogen synthase kinase-3 (GSK-3)
  • NF-κB pathway
03

In context

Lead sponsor

Anwaar Saeed is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily written and willingness/ability to comply with the protocol requirements
  • Has confirmed advanced, recurrent, or pancreatic cancer AND is previously untreated with systemic agents in the advanced/metastatic setting.
  • Must have at least 1 per v1.1. Lesions that are radiated should not count as target lesions unless there is evidence of growth post radiation on a subsequent scan prior to trial enrollment.
  • Must have available archived tumor tissue at study entry (metastatic tissue preferred to primary tissue)
  • Adequate bone marrow function: (ANC) ≥ 1000/mL; ≥ 8.5 g/dL, ≥ 100,000/mL.
  • Adequate liver function: transaminases (/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 2.5 x (≤ 5 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells); ≤ 1.5 x ULN.
  • Adequate renal function: CrCl > 60 mL/min measured or calculated by Cockcroft- Gault (C-G) equation (estimated [eGFR] can also be used in place of CrCl).
  • Serum amylase and lipase ≤ 1.5 x ULN
  • Eastern Co-operative Oncology Group () performance status (PS) 0 - 1
  • Has received the final dose of any of the following treatments/ procedures within the specified minimum intervals before first dose of study drug: Focal radiation therapy - 7 days Surgery with general anesthesia - 7 days Surgery with local anesthesia - 7 days

Exclusion criteria

Exclusion Criteria:

  • Is pregnant or lactating.
  • Is known to be hypersensitive to any of the components or metabolites of 9-ING-41 or to the used in its formulation, or known sensitivity to one of the chemotherapeutic agents or to the inhibitor.
  • History of receiving prior treatment with any anti-PD-1, PD-L1 or PD-L2 agent.
  • Has endocrine or acinar pancreatic carcinoma.
  • Has not recovered from toxicities as a result of prior anticancer therapy, except alopecia, anemia not requiring transfusion support and infertility. Recovery is defined as ≤ Grade 1 or baseline severity per (CTCAE) Version 5.0 (v5.0).
  • Has significant cardiovascular impairment: history of congestive heart failure greater than (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening.
  • Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator.
  • Has symptomatic rapidly progressive or as assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI). Patients with stable brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and are at a stable dose for a period of 14 days prior to the first dose of study drug.
  • Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered).
  • Has any medical and/or social condition that, in the opinion of the investigator would preclude study participation.
  • Has received an anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial.
  • Has a current other than pancreatic cancer.
  • Known immunodeficiency syndrome or active disease or requiring systemic in excess of physiologic maintenance doses of corticosteroids (> 10 mg/day of prednisone or equivalent).
  • Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis.
  • Palliative radiation therapy administered within 1 week of first dose of study treatment or radiation therapy that is > 30 Gy within 6 months of the first dose of study treatment.
  • Has received systemic antibiotics ≤ 7 days prior to the first dose of study drug.
  • History of organ transplant, including stem cell transplantation.
  • Known to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
  • Known allergy or hypersensitivity to any component of retifanlimab or formulation components.
  • Has received a within 28 days of the planned start of study drug.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    9-ING-41 plus Retifanlimab plus Gem/Abraxane

    * intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter, followed by an infusion of gemcitabine according to the gemcitabine label at a dose of 1000 mg per square meter, on days 1, 8, 15 of a 28-day cycle. * Retifanlimab 500 mg IV on day 1 of a 28-day cycle. (Retifanlimab will be administered following gemcitabine/nab-paclitaxel.) * 9-ING-41 administered at a dose of 9.3 mg/kg by IV infusion twice weekly on Days 1 and 4 of each week of a 28-day cycle. (9-ING-41 will be administered following retifanlimab.)

    Drug: 9-ING-41 · Drug: Retifanlimab · Drug: Gemcitabine · Drug: Abraxane

Interventions

06

What researchers measure

Primary outcomes

  1. Disease Control Rate (DCR)

    Percentage of patients with stable disease (SD), Complete Response (CR), or Partial Response (PR) for ≥16 weeks during treatment. Per RECIST v1.1, (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: Up to approximately 11 months from baseline

Secondary outcomes

  1. Best Response

    Number of patients with Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: Up to 12 months (from enrollment)

  2. Overall Response Rate (ORR)

    Percentage of patients with Complete Response (CR) or Partial Response (PR) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Up to 12 months (from enrollment)

  3. Adverse Events and Serious Adverse Events

    Number of participants with overall treatment-related adverse events (AE) and/or serious adverse events (SAE) at least possibly related as assessed by CTCAE v5.0.

    Time frame: Up to 12 months (from enrollment)

  4. Duration of Response (DOR)

    Time from documentation of tumor response to disease progression. Per RECISIT v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: Up to 12 months (from enrollment)

  5. Progression-free Survival (PFS)

    Time from study enrollment until objective tumor progression or death. Per RECISIT v1.1, Progressive Disease (PD) is ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

    Time frame: Up to 12 months (from enrollment)

  6. Overall Survival (OS)

    Time patients are alive from study enrollment to death from any cause.

    Time frame: Up to 24 months

07

Results

Posted Jul 17, 2025

Participant flow

Participant flow — Overall Study
Milestone9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Started7
Completed7
Not completed0

Outcome measures

PrimaryDisease Control Rate (DCR)

Percentage of patients with stable disease (SD), Complete Response (CR), or Partial Response (PR) for ≥16 weeks during treatment. Per RECIST v1.1, (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
Up to approximately 11 months from baseline
Reported as:
Number · percentage of patients
Disease Control Rate (DCR)
percentage of patients9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Disease Control Rate (DCR)100
SecondaryBest Response

Number of patients with Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
Up to 12 months (from enrollment)
Reported as:
Count of participants · Participants
Best Response
Participants9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Complete Response0
Partial Response2
Stable Disease4
Progressive Disease0
SecondaryOverall Response Rate (ORR)

Percentage of patients with Complete Response (CR) or Partial Response (PR) per RECIST v1.1 Per RECIST v1.1: Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Up to 12 months (from enrollment)
Reported as:
Number · percentage of patients
Overall Response Rate (ORR)
percentage of patients9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Overall Response Rate (ORR)33
SecondaryAdverse Events and Serious Adverse Events

Number of participants with overall treatment-related adverse events (AE) and/or serious adverse events (SAE) at least possibly related as assessed by CTCAE v5.0.

Time frame:
Up to 12 months (from enrollment)
Reported as:
Number · participants
Adverse Events and Serious Adverse Events
participants9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Alanine aminotransferase increased2
Alopecia2
Anemia5
Anorexia1
Aspartate aminotransferase increased1
Ataxia1
Blurred vision1
Colitis1
Constipation1
Diarrhea5
Dizziness1
Edema limbs3
Eye disorder1
Fatigue4
Febrile neutropenia1
Fever2
Flu like symptoms1
Headache1
Hyperkalemia1
Hypokalemia2
Hypomagnesemia2
Hyponatremia1
Mucositis oral3
Nail changes1
Nail discoloration1
Nausea4
Neutrophil count decreased4
Papulopustular rash1
Periorbital Dermatitis1
Peripheral motor neuropathy1
Peripheral sensory neuropathy1
Platelet count decreased3
Pruritus3
Rash maculo-papular2
Sepsis2
Skin and subcutaneous tissue disorders - Other, specify1
Syncope1
Throat pain1
Vomiting2
Weight loss4
White blood cell decreased2
SecondaryDuration of Response (DOR)

Time from documentation of tumor response to disease progression. Per RECISIT v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or nontarget) with reduction in short axis to \<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
Up to 12 months (from enrollment)
Reported as:
Median · months
Duration of Response (DOR)
months9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Duration of Response (DOR)5.273 (4.862 to 5.684)
SecondaryProgression-free Survival (PFS)

Time from study enrollment until objective tumor progression or death. Per RECISIT v1.1, Progressive Disease (PD) is ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.

Time frame:
Up to 12 months (from enrollment)
Reported as:
Median · months
Progression-free Survival (PFS)
months9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Progression-free Survival (PFS)6.785481 (4.970569 to 8.69)
SecondaryOverall Survival (OS)

Time patients are alive from study enrollment to death from any cause.

Time frame:
Up to 24 months
Reported as:
Median · months
Overall Survival (OS)
months9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Overall Survival (OS)10.72596 (6.965337 to 20.40549)

Adverse events

Collected over Adverse Events data collected for up to 12 months. All-Cause Mortality data collected for up to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
9-ING-41 Plus Retifanlimab Plus Gem/Abraxane4/7 (57.1%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Most frequent serious events
Event9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
SepsisInfections and infestations2/7
Blood bilirubin increasedInvestigations1/7
AnemiaBlood and lymphatic system disorders1/7
ColitisGastrointestinal disorders1/7
Thromboembolic eventVascular disorders1/7
Most frequent other events
Showing 10 of 56
Most frequent other events
Event9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
DiarrheaGastrointestinal disorders5/7
AnemiaBlood and lymphatic system disorders4/7
FatigueGeneral disorders4/7
NauseaGastrointestinal disorders4/7
Neutrophil count decreasedInvestigations4/7
Weight lossGeneral disorders4/7
Alanine aminotransferase increasedInvestigations3/7
Edema limbsVascular disorders3/7
Mucositis oralGastrointestinal disorders3/7
Muscle crampMusculoskeletal and connective tissue disorders3/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Mean57.14286 ± 5.607939
Sex: Female, Male
Sex: Female, Male(Participants)9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Female3
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
Hispanic or Latino2
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)9-ING-41 Plus Retifanlimab Plus Gem/Abraxane
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White4
More than one race0
Unknown or Not Reported2
08

Study locations

2 sites
  • Kansas University Cancer Center
    Fairway, Kansas 66205, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Publications

  • Shaw G, Cavalcante L, Giles FJ, Taylor A. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells. J Hematol Oncol. 2022 Sep 14;15(1):134. doi: 10.1186/s13045-022-01352-x. PubMed 36104795 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Dec 2022, 10 months.

Results were first posted in Jul 2025, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2022
First posted
Feb 14, 2022
StartActual
Jan 26, 2022
Primary completionActual
Dec 20, 2022
CompletionActual
Feb 4, 2024
Results first posted
Jul 17, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05239182
Lead sponsor
Anwaar Saeed
Collaborators
Actuate Therapeutics Inc., Incyte Corporation
Responsible party
Anwaar Saeed (Associate Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Feb 14, 2022
Start date
Jan 26, 2022
Primary completion
Dec 20, 2022
Completion
Feb 4, 2024
Results posted
Jul 17, 2025
Last update
Jul 17, 2025

Study contacts

Anwaar Saeed, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elraglusib · Retifanlimab

Start the discussion